0000000000205697

AUTHOR

Antonio Vena

showing 4 related works from this author

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with…

2020

Contains fulltext : 229471.pdf (Publisher’s version ) (Closed access) OBJECTIVES: To summarize the available evidence on the diagnostic performance for invasive aspergillosis (IA) in non-hematological, non-solid organ transplantation critically ill patients of the following: (i) existing definitions of IA (developed either for classical immunocompromised populations or for non-immunocompromised critically ill patients); (ii) laboratory tests; (iii) radiology tests. METHODS: A systematic review was performed by evaluating studies assessing the diagnostic performance for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference definition. RES…

0301 basic medicineMicrobiology (medical)Adultmedicine.medical_specialtyCritical Illness030106 microbiologyAspergillosisSensitivity and SpecificityOrgan transplantationMannans03 medical and health sciencesGalactomannanchemistry.chemical_compound0302 clinical medicineDiagnosisMedicineHumansAspergillosis030212 general & internal medicineIntensive care medicineInvasive Pulmonary AspergillosisAdult patientsmedicine.diagnostic_testbusiness.industryCritically illIABiomarkerInvasive pulmonary aspergillosismedicine.diseaseAspergillulnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesBronchoalveolar lavageAspergilluschemistryIPAAspergillus; Biomarker; Diagnosis; IA; IPA; Invasive aspergillosis; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisBiomarker (medicine)Aspergillus; Biomarker; Diagnosis; IA; Invasive aspergillosis; IPA; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisInvasive aspergillosisbusinessBronchoalveolar Lavage FluidDiagnosi
researchProduct

Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project

2019

Contains fulltext : 206779.pdf (Publisher’s version ) (Open Access) BACKGROUND: The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive care units (ICUs) in Europe. METHODS: A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries, representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU). RESULTS: During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of 7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually exclusive cumulative incidences of candide…

MaleOutcome Assessmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]MULTICENTERCritical Care and Intensive Care Medicinelaw.invention610 Medical sciences Medicine0302 clinical medicineRetrospective StudieRisk FactorslawOutcome Assessment Health CareEPIDEMIOLOGYMedicineCumulative incidencePREDICTORSCandidaMedicine(all)Cross InfectionIncidenceIncidence (epidemiology)lcsh:Medical emergencies. Critical care. Intensive care. First aidCandidiasisMiddle AgedIntensive care unitEuropeIntensive Care UnitsAbdominal candidiasis; Candida; Candidemia; Candidiasis; ICU; Incidence; Aged; Candidiasis Invasive; Cross Infection; Europe; Female; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Outcome Assessment Health Care; Retrospective Studies; Risk FactorsCandidiasiFemaleSOFA scoreLife Sciences & BiomedicineHumanAbdominal candidiasismedicine.medical_specialtyInvasiveIntensive Care Unit610Abdominal candidiasis Candida Candidemia Candidiasis ICU Incidence03 medical and health sciencesCritical Care MedicineGeneral & Internal MedicineIntensive careSettore MED/41 - ANESTESIOLOGIAMANAGEMENTHumansCandidiasis InvasiveAgedRetrospective StudiesScience & TechnologyAbdominal candidiasis; Candida; Candidemia; Candidiasis; ICU; Incidencebusiness.industrySeptic shockINTRAABDOMINAL CANDIDIASISResearchCandidemia030208 emergency & critical care medicineRetrospective cohort studylcsh:RC86-88.9Odds ratiomedicine.diseaseHealth Carelnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]ICUEmergency medicineAbdominal candidiasibusinessCritical Care
researchProduct

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapene…

2020

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus

Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugAntibiotics
researchProduct

Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study

2022

INTRODUCTION: Intra-abdominal infections represent the second most frequently acquired infection in the intensive care unit (ICU), with mortality rates ranging from 20% to 50%. Candida spp. may be responsible for up to 10-30% of cases. This study assesses risk factors for development of intra-abdominal candidiasis (IAC) among patients admitted to ICU. METHODS: We performed a case-control study in 26 European ICUs during the period January 2015-December 2016. Patients at least 18 years old who developed an episode of microbiologically documented IAC during their stay in the ICU (at least 48 h after admission) served as the case cohort. The control group consisted of adult patients who did no…

Microbiology (medical)MORTALITYInvasive candidiasiCandida; Intra-abdominal infection; Invasive candidiasis; Risk factorsCONTROLLED-TRIALCASPOFUNGINCANDIDEMIAInvasive candidiasisInfectious Diseaseslnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Intra-abdominal infectionRisk factorsINFECTIONSMANAGEMENTEPIDEMIOLOGYPREDICTORSCONSENSUSCRITICALLY III PATIENTSCandida
researchProduct